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Abstract
Background: There is little information describing survival in HIV-infected patients after primary
diagnosis in Korea, and changes in survival over time. This study investigated survival times, survival
characteristics, and changes in survival after initial HIV diagnosis. Survival was characterized by
evaluation of the immune status at primary HIV diagnosis nationwide.
Methods: A total of 5,323 HIV-infected individuals were registered with the government and
followed until the end of 2007. Survival following HIV diagnosis was estimated based on
epidemiological characteristics. We examined 3,369 individuals with available initial CD4+ T-cell
counts within 6 months of HIV diagnosis to estimate survival based on immune status at diagnosis.
The association between epidemiological variables and survival times was analyzed with univariate
and multivariate Cox's proportional hazards model.
Results: Individuals died during the study period (n = 980), and 45% of the individuals died within
6 months of HIV diagnosis. The median survival following HIV diagnosis was 16.7 years. Survival
were longer in women, in younger persons, in individuals diagnosed at blood centers, and in
individuals diagnosed later in the study period. Survival were shortest in individuals with CD4+ T-
cell counts <200 cells/mm3 at HIV diagnosis. These results suggest that early HIV diagnosis in Korea
is imperative to increase survival and to promote the quality of life for HIV-infected individuals with
governmental support.
Conclusion: The median survival time of HIV-infected individuals following HIV diagnosis was 16.7
years in Korea. The survival was significantly lower in individuals with CD4+ T-cell counts <200
cells/mm3 at HIV diagnosis and higher by introduction of drugs and development of therapy.
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Background
There are nearly 60 million individuals infected with
Human Immunodeficiency Virus (HIV) since the early
1980s, and at least 25 million HIV-infected individuals
have died of Acquired Immunodeficiency Syndrome
(AIDS) since the beginning of the epidemic [1]. AIDS has
decreased life expectancies by 20 years, and the high rates
of HIV infection in adolescents and women of reproduc-
tive age have resulted in community destruction, family
dissolution, and economic loss in many sub-Saharan Afri-
can countries. AIDS prevention program has been actively
performed, and there has been significant ongoing
research focused on the development of an HIV vaccine
and effective antiretroviral drugs. As a result, the dead by
AIDS has decreased from 2.2 million in 2005 to 2 million
in 2007 and newly HIV-infected individuals have also
reduced recently [1]. AIDS-associated mortality increased
by 16% year by year to the mid-1990s and then was raised
as first cause of adult death, however, it has rapidly
decreased since the mid-1990s in the United States [2].
This decrease in AIDS-associated mortality coincided with
the introduction of highly active antiretroviral therapy
(HAART), including protease inhibitors [3], suggesting
that survival following HIV infection increased from 10–
12 years to 25 years [4,5].
A total of 5,323 individuals have been diagnosed with
HIV infection between 1985 and 2007 in Korea. Approxi-
mately 91% of infected individuals were male and 99%
were infected by sexual contact [6]. HIV-infected individ-
uals may refuse antiretroviral therapy because of efficacy
concerns and social stigmas. Additionally, patients and
their families may remain unconvinced by positive
antiretroviral effects on survival times [7]. There are no
current estimates describing the survival of HIV-infected
individuals in Korea, and we therefore assumed that HIV
survival times might have increased with the advent of
governmental support for therapy and the introduction of
HAART in 1997. The number of newly diagnosed HIV-
infected individuals in Korea and the target population
for therapy is increasing, and it is therefore necessary to
assess the national HIV/AIDS prevention program of ther-
apy for HIV-infected individuals. It is therefore necessary
to estimate HIV/AIDS survival in Korea in order to predict
governmental budgets for therapy.
It is difficult to predict the time of HIV infection in this
population since the majority of reported HIV infections
in Korea are the result of sexual contact. This study inves-
tigated survival times, survival characteristics, and the
changes in survival times following HIV diagnosis. This
study also evaluated the immune status of individuals at
HIV diagnosis to elucidate the association between sur-
vival and CD4+ T-cell counts at primary HIV diagnosis.
Methods
HIV diagnosis and the National control of HIV/AIDS
HIV-reactive samples from screening testing centers were
referred to local Institutions of Health and the Environ-
ment (IHEs) or the Division of AIDS at the Korea Centers
for Disease Control and Prevention (KCDC) to confirm
HIV infection. Results of HIV infection were transferred to
the Division of HIV & TB Control at the KCDC. Individu-
als were automatically registered as infected unless they
were anonymously tested. Epidemiological investiga-
tions, public health education programs, connection to
medical center, and therapy costs were supported by Pub-
lic Health Centers (PHCs). HIV-associated deaths were
documented by PHCs, and medical certificates with the
dates, places, and reasons of death were reported to the
Division of HIV & TB Control in KCDC. Additionally,
immune testing of registered individuals was performed
on a regular basis by the Division of AIDS at the KCDC or
by medical centers [6].
Subjects
A total of 5,323 HIV-infected individuals were registered
at the KCDC from 1985 to 2007 in Korea. Data from these
individuals were investigated to estimate survival and
their association with epidemiologic characteristics fol-
lowing HIV diagnosis. Survival according to immune sta-
tus at HIV diagnosis were estimated in individuals with
initial CD4+ T-cell counts at HIV diagnosis (n = 3,369).
They were older than 14 years of age at HIV diagnosis and
had available initial CD4+ T-cell counts within 6 months
of HIV diagnosis including individuals died of AIDS
within 6 months after HIV diagnosis.
Selection criteria
The date of HIV diagnosis was defined as the date when
the KCDC or local IHEs confirmed a sample as HIV-posi-
tive. Survivals were analyzed with epidemiological varia-
bles including gender, age, screening site, year of
diagnosis, and immune status at HIV diagnosis. Screening
sites were classified into three groups: public institutions,
hospitals, and blood centers [8]. Year of diagnosis were
grouped by changes in drug introduction and therapeutic
administration. Zidovudine (AZT) monotherapy was
introduced to the Korean HIV therapeutic system in 1991
[9], and HAART was introduced in 1997 [10]. HIV RNA
quantitative assays have been performed at the Division
of AIDS at the KCDC or in medical centers to monitor the
efficacy of therapy since late 2002. Categories included:
no antiretroviral therapy (1985–1990), AZT mono-BMC Infectious Diseases 2009, 9:128 http://www.biomedcentral.com/1471-2334/9/128
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therapy (1991–1996), HAART (1997–2002), and use of
HIV RNA quantitative tests for monitoring (2003–2007).
The immune status of infected individuals was stratified
into four categories by CD4+ T-cell counts (<200 cells/
mm3, 200–349 cells/mm3, 350–499 cells/mm3, and ≥500
cells/mm3) based on the 1993 revised classification sys-
tem for HIV infection [11] and the 2002 guidelines for the
use of antiretroviral agents in HIV-infected adults and
adolescents by Centers for Disease Control and Preven-
tion of United States [12].
Statistical analysis
Follow-up of HIV-infected individuals for survival analy-
sis of 5,323 individual was performed until December 32,
2007. Kaplan-Meier analysis and log-rank tests were used
to compare survival curves stratified by epidemiological
group. The Cox's proportional hazards model was applied
to examine the association between variables and survival
times. We classified 1,954 individuals without CD4+ T-
cell counts or CD4+ T-cell counts taken greater than 6
months after HIV diagnosis into the "missing group" in
the multivariate analysis to adjust the confounding. The
results of the missing group were not shown in Table 1.
Analysis was performed using the SAS version 9.1 soft-
ware packages, and the STATISTICA program was used for
survival graph.
Results
Epidemiological characteristics of study populations
The majority (91%) of HIV-infected individuals (n =
4,861) were men (Table 1). The greatest proportion of
HIV-infected individuals were aged 30–39 years (33%),
and 65% of all infections were identified in hospitals.
Additionally, 62% were diagnosed between 2003 and
2007 and 18% (n = 980) died before the end of the study.
Additionally, 45% of individuals died within 6 months of
HIV diagnosis, and many of these patients were aged 40
years and older, were initially detected in hospitals (56%),
and were diagnosed between 2003 and 2007 (75%).
The survival by epidemiologic characteristics and immune 
status at HIV diagnosis
The median survival of HIV-infected individuals follow-
ing diagnosis was 16.7 (data not shown). Figure 1 showed
survival of HIV-infected individuals by epidemiological
characteristics. Women had longer survival than men (p =
0.0442), a younger age at initial HIV diagnosis was asso-
ciated with a significantly longer survival (p < 0.0001).
HIV-infected individuals identified in blood centers dem-
onstrated the longest survival, followed by individuals
from public institutions and hospitals (p < 0.0001). Indi-
viduals diagnosed between 2003 and 2007 demonstrated
longer survival (p = 0.0039).
Survivals stratified by CD4+ T-cell counts at HIV diagnosis
were shown in Figure 2. HIV-infected individuals with
CD4+ T-cell counts <200 cells/mm3  at HIV diagnosis
demonstrated 46% survival at 10 years after diagnosis.
However, individuals with CD4+ T-cell counts ≥200 cells/
mm3 demonstrated approximately 77% survival in the
same time period (data not shown).
Table 2 showed the proportion of 10 years survival after
HIV diagnosis. It also analyzed estimation Cox's hazard
Table 1: Characteristics of the study population, 1985–2007
Categories All (%) No. of deaths
(%)
No. of deaths within
6 months of diagnosis(%)*
Person-years Mortality density
(per 1,000 person-years)
Total individuals 5,323 980 (18) 441 (45) 21,439 45.7
Gender
Men 4,861 (91) 901 (19) 413 (46) 19,082 47.2
Women 462 (9) 79 (17) 29 (37) 2,357 33.5
Age
≤ 29 1,363 (26) 148 (11) 25 (17) 7,153 20.7
30–39 1,758 (33) 283 (16) 102 (36) 7,506 37.7
40–49 1,220 (23) 268 (22) 136 (51) 4,081 65.7
≥ 50 982 (18) 281 (29) 179 (64) 2,699 104.1
Screening site
Public institution 1,394 (26) 296 (21) 51 (14) 8,031 36.8
Hospital 3,448 (65) 644 (19) 390 (56) 10,632 60.6
Blood center 481 (9) 40 (8) 1 (9) 2,776 14.4
Year of diagnosis
1985–1990 124 (2) 86 (69) 5 (6) 1,403 61.3
1991–1996 497 (10) 215 (43) 35 (16) 4,878 44.1
1997–2002 1,388 (26) 339 (24) 146 (43) 8,202 41.3
2003–2007 3,314 (62) 340 (10) 256 (75) 6,956 48.9
*%; proportion of the number of the deaths within 6 months after HIV diagnosis divided by the number of deathsBMC Infectious Diseases 2009, 9:128 http://www.biomedcentral.com/1471-2334/9/128
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ratio by epidemiological variables. The adjusted relative
hazard ratio (AHR) by gender was approximately 1.4-fold
higher in men than in women (p = 0.0082). Individuals
aged 29 years or younger had lower AHRs than individu-
als aged 30–39 years (AHR, 1.46; p = 0.0003), and indi-
viduals aged 40–49 years (AHR, 2.10; p < 0.0001),
individuals aged 50–59 years (AHR, 3.08; p < 0.0001).
Survival stratified by screening site was higher in PHCs
than in hospitals (AHR, 1.50; p < 0.0001), and longer sur-
vival was observed in individuals diagnosed in blood
centers (AHR, 0.62; p = 0.0067). Survival were shorter in
the individuals diagnosed prior to 1990 than in individu-
als diagnosed between 2003 and 2007 (AHR, 5.03; p <
0.0001). Survival was shorter in individuals with CD4+ T-
cell counts <200 cells/mm3 than in individuals with CD4+
T-cell counts ≥500 cells/mm3 (AHR, 5.10; p < 0.0001).
Individuals with CD4+ T-cell counts ≥200 cells/mm3 dis-
played similar survival.
Table 3 showed the comparison of survivals by epidemio-
logical variables in year of diagnosis. Survival in individu-
als aged 30–39 years and in individuals with 200–349
cells/mm3 of CD4+ T-cell counts have increased after
HAART.
Discussion and conclusion
The survival following HIV diagnosis in Korea was 16.7
years in this study. Survival in individuals diagnosed
between 2003 and 2007 was 5.0- and 3.5-fold higher in
individuals diagnosed prior to 1990 and between 1991
and 1996, respectively. This suggested the presence of pos-
itive therapeutic effects in survival of HIV-infected indi-
viduals based on introduction of government supported-
antiretroviral therapy. Several hospitals were designated
as AIDS care centers in 1989 during the early periods of
therapeutic support in Korea [13]. However, this system
was abolished due to the prohibition of discrimination
against HIV-infected individuals in 1999. The number of
HIV treatment hospitals increased to 60 hospitals in 2007
[14]. Survival was increased during AZT treatment periods
(1991–1996) compared to non-treatment periods (1985–
1990), in spite of no effect of AZT on survival in other
studies [15]. This may be the result of increased immunity
due to dietary health support products such as Korean red
ginseng, increased support for HIV-infected individuals,
and rapid contact with hospitals rather than due to thera-
peutic effect of AZT [16,17]. During HAART era, the sur-
vival was longer in 2003–2007 compared to survival in
1997–2002. This could be associated with appropriate
Table 2: Proportion of survival following HIV diagnosis and the estimated hazard ratios for variables
Unadjusted Adjusted
Variable No. of cases Proportion surviving after 10 years (95% CI) Hazard Ratio
(95% CI)
p-value Hazard Ratio
(95% CI)
p-value
Gender
Men 4,861 67%(64–69) 1.31(1.04,1.65) 0.0211 1.37(0.09,1.73) 0.0082
Women 462 73%(66–78) 1.00 - 1.00 -
Age
≤ 29 1,363 81%(77–84) 1.00 - 1.00 -
30–39 1,758 71%(66–74) 1.80(1.47,2.20) < .0001 1.46(1.19,1.80) 0.0003
40–49 1,220 56%(50–63) 2.94(2.40,3.61) < .0001 2.10(1.70,2.60) < .0001
≥ 50 982 49%(41–57) 4.37(3.56,5.35) < .0001 3.08(2.48,3.83) < .0001
Screening site
Public institution 1,394 68%(64–71) 1.00 - 1.00 -
Hospital 3,448 68%(64–72) 1.47(1.27,1.70) < .0001 1.50(1.27,1.76) < .0001
Blood center 481 85%(78–89) 0.39(0.28,0.55) < .0001 0.62(0.44,0.88) 0.0067
Year of diagnosis
1985–1990 124 56%(46–64) 2.15(1.65,2.80) < .0001 5.03(3.77,6.71) < .0001
1991–1996 497 62%(57–66) 1.57(1.29,1.90) < .0001 3.48(2.81,4.30) < .0001
1997–2002 1,338 70%(66–73) 1.31(1.11,1.54) 0.0011 1.42(1.21,1.68) < .0001
2003–2007 3,314 - 1.00 - 1.00 -
CD4+ T-cell counts*
<200 1,169 46%(41–51) 5.51(4.47,6.78) < .0001 5.10(4.11,6.33) < .0001
200–349 868 70%(63–75) 1.06(0.81,1.38) 0.6872 1.13(0.86,1.47) 0.3865
350–499 667 80%(74–84) 0.77(1.81,2.92) 0.0757 0.80(0.60,1.06) 0.1223
≥500 665 80%(75–84) 1.00 - 1.00 -
CI: Confidence Interval
*Individuals were classified by initial CD4+ T-cell counts within 6 months of HIV diagnosis, including individuals who died from AIDS within 6 
months of HIV diagnosis. Individuals without CD4+ T-cell counts or CD4+ T-cell counts measured greater than 6 months of HIV diagnosis were 
designated as the "missing group" (data not shown).BMC Infectious Diseases 2009, 9:128 http://www.biomedcentral.com/1471-2334/9/128
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HIV RNA quantitation and drug resistance testing for effi-
cient therapy. In addition, the increased 17 available
drugs compared to 15 available drugs before 2003 may
have positive effect on survival in 2003–2007 [18]. The
most efficient therapeutic effect in the group with CD4+ T-
cell counts of 200–349 cells/mm3 was due to the initia-
tion and continued HAART in newly diagnosed individu-
als with CD4+ T-cell counts <350 cells/mm3 according to
CDC guidelines. However, HAART in newly-diagnosed
individuals with CD4+ T-cell counts <200 cells/mm3 did
not appear efficacious.
The immune status of newly diagnosed individuals
revealed low CD4+ T-cell counts, suggesting that HIV
diagnosis was delayed after primary infection [8]. Individ-
uals with CD4+ T-cell counts ≥200 cells/mm3 had longer
survival than individuals with CD4+ T-cell counts <200
cells/mm3. Survival of individuals with CD4+ T-cell
counts <200 cells/mm3 was increased to 13 years com-
pared to previous results from Korea (3.6 years) and USA
(2.7 years) prior to HAART [8,19].
The proportion of individuals who died within 6 months
after HIV diagnosis was higher in Korea (45%) than in
France (14%) or the United Kingdom (10–20%) [20,21].
Approximately 70% of individuals who died within 6
months of diagnosis were diagnosed within 2 months
prior to death (data not shown). Mortality was related to
age [22] and decreased CD4+ T-cell counts, suggesting
that older HIV-infected individuals were generally diag-
nosed at the late stages of disease. This suggested that early
diagnosis is required to prevent HIV transmission and
allow for appropriate HIV treatment in Korea.
AIDS mortality due to HIV-related causes has been
reduced by HAART. However, non-HIV-related mortality
has increased [23]. AIDS-associated mortality in Korea
encompassed 70% of all deaths in HIV-infected individu-
als, and heart disease, liver disease, cerebral disease, and
respiratory and pulmonary diseases were secondary
causes of death. AIDS-related mortality in HIV-infected
individuals has slowly decreased, although AIDS is still
the primary cause of death in Korea [20]. Non-HIV-related
Survival after HIV diagnosis stratified by epidemiologic characteristics Figure 1
Survival after HIV diagnosis stratified by epidemiologic characteristics. A, Gender; B, Age; C, Screening site; and D, 
Year of diagnosis.BMC Infectious Diseases 2009, 9:128 http://www.biomedcentral.com/1471-2334/9/128
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deaths among HIV-infected individuals included drug-
associated deaths in New York (1999 to 2004), cancer in
Australia and the United States (2004), hepatic disease in
Europe, and hepatic disease associated with hemophilia
[24-28]. However, AIDS was still the primary cause for
mortality due to late diagnosis after primary infection.
There are several limitations in this study. Survivals were
estimated indirectly based on changes in drug introduc-
tion and development of therapy. Drug therapy for HIV
infections follows CDC guidelines in Korea [29], so
grouping based on drug therapy introduction times is rea-
sonable. However, further study is required to characterize
survival based on Korean therapeutic effects, and main
survival factors require the investigation of therapy accept-
ance or rejection, the date of antiretroviral therapy initia-
tion, antiretroviral dosages, treatment protocols, and
compliance. The study also required the investigation of
survival based on smoking and alcohol consumption as
primary epidemiological factors of survival. Second, sur-
vival stratified by cause of death was not analyzed in this
study due to numerous AIDS-associated syndromes and
subjective decisions by physicians. Additionally, cardio-
vascular disease, diabetes, and hepatic disease can also
cause death in AIDS patients, as can myocardial infarction
and metabolic complications as therapeutic side effects
[30]. Therefore, the standardization of causes of death in
HIV-infected individuals should analyze survival based
on cause of death. Lastly, individuals without CD4+ T-cell
counts or with CD4+ T-cell counts collected greater than 6
months after HIV diagnosis were designated the "missing
group" during analysis. However, there were no differ-
ences between individuals with initial CD4+ T-cell counts
measured within 6 months after HIV diagnosis (including
individuals who died during this time period) and the
"missing group" in survival stratified by immune status at
diagnosis (HR: 0.94; [95% confidence interval, 0.80–
1.11]; p = 0.4693).
Survival after HIV diagnosis in Korean populations has
been recently increasing. A delayed diagnosis results in
missed therapeutic opportunities, while an early diagno-
sis may increase survival and the quality of life in HIV-
infected individuals supported by governmental pro-
grams. The best way to improve rates of early diagnosis in
asymptomatic individuals is to test as many individuals as
possible. Korean government made a stipulation for
anonymous testing system in March 2008 to minimize
the fear for identity exposure by HIV testing [31]. Anony-
mous testing services need to be improved in PHC and
voluntary counseling and testing centers.
This study is the first to investigate survival of HIV-
infected individuals in Korea. Future studies should eval-
uate survival characteristics based on disease progression
to AIDS, administration of antiretroviral drugs, therapeu-
tic protocols, and antiretroviral drug resistance.
A, Level of CD4+ T-cell counts at HIV diagnosis over calendar year, and B, Survival stratified by CD4+ T-cell counts at HIV  diagnosis (The survival curve of "missing group" was not shown) Figure 2
A, Level of CD4+ T-cell counts at HIV diagnosis over calendar year, and B, Survival stratified by CD4+ T-cell 
counts at HIV diagnosis (The survival curve of "missing group" was not shown).B
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Table 3: Survival following HIV diagnosis and the estimated hazard ratio of variables by year of diagnosis
1985–1990 1991–1996 1997–2002 2003–2007
Variables Cox's 
Regression
Case No.(%) HR (95%CI) P-value Case No.(%) HR (95%CI) P-value Case No.(%) HR
(95%CI)
P-value Case No.(%) HR
Gender
Men Unadjusted 105
(85)
2.2
(1.7–2.9)
< .0001 440
(89)
1.5
(1.2–1.9)
< .0001 1230
(89)
1.3
(1.1–1.6)
0.001 3082
(93)
1
Adjusted 4.3
(3.2–5.9)
< .0001 3.0
(2.4–3.7)
< .0001 1.3
(1.1–1.5)
0.0022 1
Women Unadjusted 19
(15)
2.4
(1.0–6.0)
0.0513 57
(11)
2.3
(1.1–4.6)
0.0209 158
(11)
1.5
(0.8–2.8)
0.2444 232
(7)
1
Adjusted 4.3
(1.6–11.4)
0.0037 4.2
(2.0–9.0)
0.0001 1.6
(0.9–3.1)
0.1402 1
Age
≤ 29 Unadjusted 60
(48)
3.7
(2.0–7.0)
< .0001 198
(40)
2.0
(1.1–3.6)
0.0188 339
(24)
1.4
(0.8–2.5)
0.2553 766
(23)
1
Adjusted 4.8
(2.5–9.3)
< .0001 2.9
(1.6–5.3)
0.0007 1.5
(0.9–2.8)
0.1514 1
30–39 Unadjusted 40
(32)
3.5
(2.2–5.7)
< .0001 184
(37)
2.6
(1.8–3.7)
< .0001 472
(34)
1.7
(1.2–2.3)
0.0016 1062
(32)
1
Adjusted 6.6
(3.9–11.1)
< .0001 4.1
(2.8–6.0)
< .0001 1.7
(1.2–2.3)
0.0016 1
40–49 Unadjusted 18
(15)
2.3
(1.3–4.1)
0.0065 76
(15)
2.5
(1.7–3.6)
< .0001 323
(23)
1.4
(1.1–1.9)
0.0181 803
(24)
1
Adjusted 2.4
(1.3–4.4)
0.0072 3.2
(2.2–4.7)
< .0001 1.4
(1.0–1.9)
0.0293 1
≥ 50 Unadjusted 6
(5)
3.7
(1.6–8.3)
0.0019 39
(8)
1.5
(1.0–2.4)
0.0755 254
(18)
1.2
(0.9–1.5)
0.2709 683
(21)
1
Adjusted 5.1
(2.2–12.0)
0.0002 2.7
(1.7–4.4)
< .0001 1.1
(0.8–1.5)
0.4569 1
Screening site
Public 
institution
Unadjusted 86
(69)
3.5
(2.2–5.8)
< .0001 295
(59)
2.4
(1.6–3.8)
0.0001 388
(28)
1.8
(1.1–2.8)
0.0148 621
(19)
1
Adjusted 4.5
(2.7–7.4)
< .0001 3.1
(2.0–4.9)
< .0001 1.7
(1.1–2.7)
0.0248 1B
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Hospital Unadjusted 17
(14)
3.7
(2.1–6.5)
< .0001 121
(24)
2.8
(2.1–3.7)
< .0001 857
(62)
1.6
(1.3–1.8)
< .0001 2451
(74)
1
Adjusted 4.0
(2.3–7.1)
< .0001 3.5
(2.7–4.7)
< .0001 1.4
(1.2–1.7)
0.0003 1
Blood 
center
Unadjusted 21
(17)
2.5
(0.5–11.3)
0.2406 81
(16)
1.5
(0.3–6.1)
0.6111 143
(10)
0.7
(0.2–3.1)
0.6275 242
(7)
1
Adjusted 4.9
(1.0–25.1)
0.0546 2.2
(0.5–9.8)
0.3165 0.9
(0.2–4.1)
0.8896 1
CD4+ T-cell 
counts*
<200 Unadjusted 10
(20)
1.6
(1.0–2.5)
0.0707 63
(18)
1.9
(1.5–2.5)
< .0001 313
(35)
1.2
(1.0–1.5)
0.0221 783
(37)
1
Adjusted 2.7
(1.6–4.4)
0.0001 2.8
(2.1–3.7)
< .0001 1.3
(1.1–1.6)
0.0063 1
200–349 Unadjusted 3
(6)
5.0
(2.2–11.7)
0.0002 71
(21)
2.7
(1.4–5.4)
0.0035 212
(24)
1.1
(0.6–2.1)
0.7649 582
(28)
1
Adjusted 6.3
(2.6–15.0)
< .0001 2.7
(1.4–5.5)
0.005 1.0
(0.5–2.0)
0.9749 1
350–499 Unadjusted 13
(25)
1.9
(0.7–5.3)
0.2351 90
(26)
1.0
(0.4–2.7)
0.9422 172
(19)
0.8
(0.3–2.1)
0.7298 392
(19)
1
Adjusted 2.6
(0.9–7.7)
0.081 1.1
(0.4–3.0)
0.8152 0.9
(0.3–2.2)
0.7546 1
≥ 500 Unadjusted 25
(49)
3.4
(1.4–8.4)
0.0076 120
(35)
2.1
(0.9–4.9)
0.1056 192
(22)
1.3
(0.5–3.1)
0.6153 328
(16)
1
Adjusted 3.5
(1.3–9.0)
0.0117 2.2
(0.9–5.4)
0.0966 1.3
(0.5–3.1)
0.6118 1
CI: Confidence Interval, HR: Hazard Ratio
*Individuals were classified by initial CD4+ T-cell counts within 6 months of HIV diagnosis, including individuals who died from AIDS within 6 months of HIV diagnosis. Individuals without CD4+ 
T-cell counts or CD4+ T-cell counts measured greater than 6 months of HIV diagnosis were designated as the "missing group" (data not shown).
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